Special items: Ovarian Cancer and Us blog best viewed in Firefox

Tuesday, January 19, 2010

abstract: Phase II biomarker trial of a multimarker diagnostic for ovarian cancer-Australia

CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8)

"CONCLUSIONS: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.